12/19
07:13 am
nrix
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia [Yahoo! Finance]
Low
Report
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia [Yahoo! Finance]
12/19
07:00 am
nrix
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Low
Report
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
12/11
08:21 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $30.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $30.00 to $35.00. They now have a "buy" rating on the stock.
12/10
08:58 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $35.00 price target on the stock.
12/10
08:01 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
12/9
06:13 pm
nrix
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting [Yahoo! Finance]
Medium
Report
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting [Yahoo! Finance]
12/9
06:00 pm
nrix
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
Medium
Report
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
12/6
08:06 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $35.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $35.00 price target on the stock.
12/4
01:28 pm
nrix
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Low
Report
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
12/2
07:10 am
nrix
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
High
Report
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
12/2
07:00 am
nrix
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Medium
Report
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
11/25
07:00 am
nrix
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Low
Report
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/20
04:02 pm
nrix
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia [Yahoo! Finance]
Low
Report
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia [Yahoo! Finance]
11/20
04:00 pm
nrix
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Low
Report
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
11/17
10:36 am
nrix
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 [Yahoo! Finance]
Medium
Report
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 [Yahoo! Finance]
11/17
10:30 am
nrix
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Medium
Report
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
11/6
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
11/5
09:00 am
nrix
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
Low
Report
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
10/31
07:00 am
nrix
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Nurix Therapeutics to Participate in Upcoming Investor Conferences
10/24
07:16 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $35.00 price target on the stock.
10/21
04:00 pm
nrix
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
Low
Report
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
10/21
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $26.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $26.00 to $30.00. They now have a "buy" rating on the stock.
10/21
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
10/21
06:22 am
nrix
Nurix Therapeutics' NX-5948 shows promise in Waldenstrom's macroglobulinaemia trial [Yahoo! Finance]
Low
Report
Nurix Therapeutics' NX-5948 shows promise in Waldenstrom's macroglobulinaemia trial [Yahoo! Finance]
10/19
08:00 am
nrix
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
Low
Report
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia